

# Victor Pimentel-Quiroz

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4137952/victor-pimentel-quiros-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27  
papers

114  
citations

5  
h-index

10  
g-index

32  
ext. papers

193  
ext. citations

3.1  
avg, IF

2.28  
L-index

#	Paper	IF	Citations
27	Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort.. <i>Lupus</i> , <b>2022</b> , 9612033211061481	2.6	0
26	Different epidemiologic profiles of systemic vasculitis between Brazil and Peru-preliminary results in two referral centers from both countries.. <i>Clinical Rheumatology</i> , <b>2022</b> , 41, 635	3.9	0
25	ANCA-Associated Vasculitis in Latin America: A Systematic Literature Review: About Their Epidemiology and Their Clinical Features.. <i>Journal of Clinical Rheumatology</i> , <b>2022</b> , 28, 44-51	1.1	1
24	LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort.. <i>Lupus Science and Medicine</i> , <b>2022</b> , 9,	4.6	0
23	Correspondence on 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitisTby Joanna C Robson and 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitisTby Ravi Suppiah.. <i>Annals of the Rheumatic</i>	2.4	1
22	Demographic and Clinical Features of ANCA-Associated Vasculitides in a Peruvian Tertiary Center. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> , 27, S246-S251	1.1	0
21	Health-Related Quality of Life and fatigue are associated with a higher work productivity impairment in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort. <i>Lupus</i> , <b>2021</b> , 30, 2157-2161	2.6	0
20	Survival in ANCA-Associated Vasculitides in a Peruvian Center: 28 Years of Experience. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> , 27, S252-S258	1.1	1
19	Performance of the 2017 American College of Rheumatology/European League Against Rheumatism Provisional Classification Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Peruvian Tertiary Care Center. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> ,	1.1	2
18	Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 4725-4734	3.9	4
17	Preconception, pregnancy, and lactation in systemic lupus erythematosus patients. <i>Revista Colombiana De Reumatología</i> , <b>2021</b> , 28, 156-156	0.2	
16	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , <b>2021</b> , 3, e707-e714	14.2	11
15	Relationship between care model and disease activity states and health-related quality of life in systemic lupus erythematosus patients.. <i>Lupus</i> , <b>2021</b> , 9612033211063798	2.6	0
14	Serum uric acid is associated with damage in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7, e000366	4.6	4
13	Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7,	4.6	2
12	Discrepant Perception of Lupus Disease Activity: A Comparison Between PatientsTand PhysiciansT Disease Activity Scores. <i>Journal of Clinical Rheumatology</i> , <b>2020</b> , 26, S165-S169	1.1	8
11	Age at diagnosis and health-related quality of life are associated with fatigue in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort. <i>Lupus</i> , <b>2020</b> , 29, 1644-1649	2.6	

10	Better Health-Related Quality of Life in Systemic Lupus Erythematosus Predicted by Low Disease Activity State/Remission: Data From the Peruvian Almenara Lupus Cohort. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1159-1162	4.7	10
9	Remission and low disease activity state prevent hospitalizations in systemic lupus erythematosus patients. <i>Lupus</i> , <b>2019</b> , 28, 1344-1349	2.6	5
8	Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. <i>Lupus</i> , <b>2019</b> , 28, 1101-1110	2.6	26
7	Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 1139-1146	3.9	1
6	Peripheral CD4+CD28null T-cells as predictors of damage in systemic lupus erythematosus patients. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 1008-1013	2.2	3
5	Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 47, 199-203	5.3	5
4	Defining Quality of Rheumatologic Care: Peru. <i>Journal of Clinical Rheumatology</i> , <b>2017</b> , 23, 212-214	1.1	1
3	Factors associated with disease expression patterns in systemic lupus erythematosus patients: results from LUMINA (LXXVII), a multiethnic US cohort. <i>Lupus</i> , <b>2017</b> , 26, 650-655	2.6	4
2	Coronary and Aortic Involvement as Initial Manifestations of Possible Giant Cell Arteritis in a Patient Without Cardiovascular Comorbidities. <i>Journal of Clinical Rheumatology</i> , <b>2016</b> , 22, 386	1.1	
1	Abatacept for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Investigational Drugs</i> , <b>2016</b> , 25, 493-9	5.9	25